An observational study in GVHD,Acute, Ulcerative Colitis and Morbus Crohn, sponsored by University of Freiburg. Completed at 1 site in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-18.
Sponsored by University of Freiburg · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 243 studies in Colitis, Ulcerative with a site in Germany — 29 open to participants now, 62 under way, 26 of them phase 3. Colitis, Ulcerative · Germany.
Among the 243 studies in Colitis, Ulcerative with a site in Germany, this one is the 33rd largest by enrollment of the 41 observational ones that give a count, is one of 18 that started in 2018, is one of 41 observational ones, and was the 159th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →29 of the 243 studies in Colitis, Ulcerative with a site in Germany are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Germany, United States, Belgium and 2 more countries
Ages 18–60
Pfizer · Sites in Germany, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Germany, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Germany, United States, Belgium and 7 more countries
Ages 18–80
Merck Sharp & Dohme LLC · Sites in Germany, United States, Canada and 9 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
243 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 93 · Phase 3 85 · Phase 4 6
First in 2000; this study’s year is marked. 18 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is below the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 179 across the 202 interventional studies, 378 across the 41 observational. Of the 163 that completed or were terminated, 88 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
197 of 243 have an industry lead sponsor. The 10 most frequent:
University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
University of Freiburg has 1 study filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
19 of the studies in Colitis, Ulcerative with a site in Germany that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
Add all 19 to your calendar (.ics) → With an account.
Among the 243 studies in Colitis, Ulcerative with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study has the aim to analyze intestinal expression of endogenous antimicrobial peptides in patients with acute GVHD. The expression will be compared to intestinal expression of defensins in patients with colitis and patients without intestinal inflammation.
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Acute GVHD is characterized by complex deficiencies of the mucosal antimicrobial barrier and intestinal dysbiosis, which contribute to disease pathogenesis. Defensins are endogenous epithelial cell-derived antimicrobial peptides, which can protect epithelial barrier integrity, shape the intestinal microbiota composition and contribute to host immunoregulation. Deregulated expression of defensins has been reported in patients with colitis, including Chron's Disease and ulcerative colitis.
In this study, the investigators aim to analyze the expression of defensins in the intestine of patients with acute GVHD to study whether it is deregulated. The results will be valuable to study the role of defensins during acute GVHD pathogenesis or as potential biomarkers for disease activity.
Adult patients who underwent diagnostic endoscopy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who underwent diagnostic endoscopy and received a diagnosis of no intestinal inflammation
Patients with active colitis
Patients with acute gastrointestinal (GI) GVHD
Defensin Expression (mRNA)
Analysis of alpha-defensin and beta-defensin mRNA expression by realtime PCR (qRT-PCR)
Time frame: 3 years
Defensin Expression (peptide)
Analysis of alpha-defensin and beta-defensin levels by immunohistochemistry
Time frame: 3 years
Plan to share: No
Ran from Sep 2018 to primary completion in Oct 2024, 73 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg